Identification of Novel Bio-markers for Environmental Enteropathy in Children Using an Evidence Based Approach
EE
Identification of Novel Biomarkers for Environmental Enteropathy in Children Using an Evidence Based Approach
1 other identifier
observational
380
1 country
1
Brief Summary
EE is increasingly recognized as a key factor underlying malnutrition, weakened immune response and impaired cognitive development in children in developing countries. Absence of a distinct biomarker of EE in the blood, urine or stool makes it difficult to study the impact of interventions against it. Biomarkers for EE have been challenging to find, partly because of our inadequate understanding of its pathophysiology. Investigators aim to identify novel biomarkers for EE, based on our hypothesis that EE is a result of two processes: 1) repeated exposure to enteric pathogens and environmental toxins leading to gut inflammation and 2) weaning on diets high in carbohydrates but low in proteins and fat, leading to atrophy of the intestinal mucosa. This leads to gut dysfunction, including leaky gut, small bowel stasis, bacterial overgrowth, decreased immune response to infections, and frequent diarrhea. The candidate biomarkers investigators have selected for our study (CRP, GLP- 2, Claudin 3, Reg-1, plasma amino acids profile, serum cytokine profile, Neopterin and Myeloperoxidase) are markers of inflammation, hormonal dysfunction and tight junction malfunction of the small intestines. The 'gold standard test' for EE will be direct histopathologic analysis of the duodenal mucosa, which will be available in a subset of study children undergoing upper GI endoscopy. For other study subjects, clinical surrogates for EE will be used to calculate the sensitivity and specificity of biomarkers being tested. These clinical surrogates of EE include HAZ and WAZ score \< 2 SD at 12 months and 15 months of age, and the worsening in HAZ and WAZ scores between 6, 9, 12 and 15 months of age. Investigators plan to study and compare duodenal biopsies from children with and without EE using cutting edge technologies including electron microscopy, immunofluorescence, and mRNA sequencing. This will allow direct correlation of the biomarkers in the blood, urine and stools with the histopathologic features of the gut mucosa. The mRNA sequencing of the gut tissue will allow us to identify new evidence-based biomarkers for EE, which could be further tested in the future. This is a strong, multidisciplinary collaboration between investigators in Pakistan and the United States with expertise in complementary areas including chemokines, inflammation, gut architecture, infectious diseases, field studies, and technology development.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2013
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2015
CompletedFirst Submitted
Initial submission to the registry
June 26, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2015
CompletedFirst Posted
Study publicly available on registry
October 11, 2021
CompletedOctober 11, 2021
October 1, 2021
2.2 years
June 26, 2015
October 6, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Correlation of Intestinal biomarkers with growth faltering from birth to 24 months
Investigators aimed to validate putative biomarkers of growth faltering, selected based on their role in gut inflammation \[fecal myeloperoxidase (MPO) and neopterin (NEO)\], enterocyte regeneration (Reg-1b) and proliferation \[Glucagon Like Peptide-2 (GLP2)\].
24 months
Correlation of systemic inflammation biomarkers with growth faltering from birth to 24 months
We also measured the association of a few systemic inflammatory biomarkers \[serum Ferritin, c-reactive protein (CRP), α1 acid glycoprotein (AGP)\] as well as Insulin-Like Growth factor 1 (IGF-1) with linear growth
24 months
Study Arms (2)
Cohort A
children with chronic malnutrition who do not respond to adequate supplemental feeding will undergo Upper Gastrointestinal Endoscopy
Cohort B
Children 6 months to 24 months old who are undergoing Upper Gastrointestinal endoscopy for any appropriate indication
Interventions
Procedure Upper gastro-intestinal endoscopic procedure involves collection of intestinal samples and it can be helpful in identifying the causes of malnutrition. Upon parental approval, the child along with two relatives will be provided transportation to Karachi, accommodation and the compensation for their time and expenses. For this procedure the child will be admitted to the hospital a day before the procedure till one day after the procedure. This procedure takes 30 minutes, requires general anesthesia and involves insertion of a flexible tube with a small TV camera and a light on one end and an eyepiece on the other. The endoscope will allow the doctor to examine the inside of certain tube-like structures in the body. Some tissue samples for laboratory testing will be taken.
Eligibility Criteria
children 6- 24 months
You may qualify if:
- chronically malnourished children at 9 months of age via HAZ score and
- no adequate response despite one month of supplemental feeding, and
- if there is history of GI illness like chronic or recurrent diarrhea
You may not qualify if:
- no parental consent
- no anesthesia clearance
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Aga Khan Universitylead
- University of Readingcollaborator
- Boston Universitycollaborator
- Washington University School of Medicinecollaborator
- University of Chicagocollaborator
- University of Virginiacollaborator
Study Sites (1)
Matiari
Matiari, Sindh, Pakistan
Biospecimen
collect blood, urine and stools at 6 and 9 months of age and test for biomarkers including GLP-2, Claudin 3, CRP, Reg 1, serum cytokines profile, plasma amino acids profile, Neopterin and Myeloperoxidase
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Syed Asad Ali
Aga Khan University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
June 26, 2015
First Posted
October 11, 2021
Study Start
January 1, 2013
Primary Completion
April 1, 2015
Study Completion
September 1, 2015
Last Updated
October 11, 2021
Record last verified: 2021-10